Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex, to the heart of a problem?

A very interesting new study (https://pubmed.ncbi.nlm.nih.gov/33010304/). Thanks for posting this.

In summary, treatment with a sigma-1 receptor agonist, fluvoxamine, produced favorable treatment outcomes in rats that had myocardial infarctions, heart attacks from decreased blood flow through the heart. For Anavex, this presents another, new disease target. Until now, most of those have been in the central nervous system. Now, the cardiovascular system — heart attacks. Are those a problem for anyone?

The sigma-1 receptor agonist in this rat study was fluvoxamine, an on-the-market selective serotonin re-uptake inhibitor, SSRI drug, used mostly as an antidepressant and anxiolytic, for depression. In comparison to the Anavex sigma-1 receptor agonists, fluvoxamine is not as active or strong. Don't you suppose Anavex right now is arranging for a replication of this study, but using blarcamesine or Anavex 3-71?

Another Anavex what-if. What if, indeed, chronic (continuous) dosing of either blarcamesine or Anavex 3-71 does in humans what it did in the rats? Might there be a market for such human therapies. How many Americans have myocardial infarctions (heart attacks) each year? How many might benefit from prophylactic (preventative, before it happens) dosings of an Anavex drug?

Cardiologists are eager to prophylactically prescribe any of the several statin drugs to those they think at risk of having a heart attack. Fine and dandy. But given the extremely tiny fraction of heart attacks actually prevented by statin dosings, if those are the SOC, standard of care, in regard to pharmaceutic prevention of heart attacks, what are the chances that the Anavex drugs could beat it?

Will an Anavex drug replace the statins? Pfizer, with it's Lipitor statin, took in $1.9 billion last year. https://www.statista.com/statistics/254341/pfizers-worldwide-viagra-revenues-since-2003/